Acoustic Cluster Therapy (ACT) With Chemotherapy for the Treatment of Locally Advanced Pancreatic Cancer

Recruiting

I'm Interested

Trial ID: NCT06850623

Purpose

The purpose of the study is to assess the efficacy and safety of Acoustic Cluster Therapy (ACT) when given in addition to chemotherapy for treatment of Locally Advanced Pancreatic Cancer.

Official Title

A Phase 2 Study to Investigate the Efficacy and Safety of Acoustic Cluster Therapy With Modified FOLFIRINOX in Patients With Locally Advanced Pancreatic Cancer

Stanford Investigator(s)

Pejman Ghanouni, MD, PhD
Pejman Ghanouni, MD, PhD

Professor of Radiology (Body MRI) and, by courtesy, of Neurosurgery, of Obstetrics and Gynecology and of Urology

Gregory M. Heestand, MD
Gregory M. Heestand, MD

Clinical Associate Professor, Medicine - Oncology

George A Fisher
George A Fisher

Colleen Haas Chair in the School of Medicine, Emeritus

Eligibility

Inclusion Criteria:

* Not deemed suitable for primary curative surgery and have radiographic and pathological disease consistent with inoperable LAPC or borderline resectable pancreatic cancer.
* Suitable to receive treatment with mFOLFIRINOX according to the Investigator's assessment.

Exclusion Criteria:

• Any prior anti-cancer treatment for pancreatic cancer (e.g. chemotherapy, surgery, radiation). Palliative bypass procedure and bile duct stenting are allowed.

Intervention(s):

combination_product: Acoustic Cluster Therapy

drug: Modified FOLFIRINOX

Recruiting

I'm Interested

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Britney Williams
650-736-3688

Stanford Cancer Center Palo Alto

Stanford, California 94305
Isabel Leonio ( Study Coordinator)

Stanford Cancer Center Palo Alto

Stanford, California 94305
Britney Williams
650-736-3688